Form 4: Cumberland Pharmaceuticals Executive Acquires and Disposes of Shares
SEC Form 4 Filing
Chris T. Bitterman, Vice President of Sales & Marketing at Cumberland Pharmaceuticals, reports changes in beneficial ownership, including the acquisition and disposal of derivative securities.
Summary
- Chris T. Bitterman, Vice President of Sales & Marketing at Cumberland Pharmaceuticals Inc. (CPIX), filed a Form 4 with the SEC.
- The filing reports changes in beneficial ownership of securities.
- On March 17, 2025, Bitterman acquired 2,750 options (right to buy) at a price of $5.17.
- The options are exercisable from March 17, 2029, and expire on March 17, 2035.
- Bitterman also disposed of 16,000 derivative securities.
- Following the reported transactions, Bitterman still owns derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock ownership changes.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and their potential impact on stock prices. These filings are closely watched by investors seeking insights into management's perspective on the company's value and future prospects.
Comparison to Industry Standards
- Comparing Bitterman's transactions to those of executives at similar pharmaceutical companies like Mylan (now Viatris) or Teva Pharmaceuticals would provide context.
- For example, if executives at these companies are also acquiring options, it could signal a positive industry outlook.
- Conversely, widespread disposal of shares might indicate concerns about future performance.
- The size of the transactions relative to Bitterman's overall holdings and the company's market capitalization is also relevant.
- A small transaction might be less significant than a large one.
Stakeholder Impact
- Shareholders may be interested in the transactions as they provide insight into management's view of the company's stock.
- The transactions themselves are unlikely to have a significant impact on other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 03/17/2025 | Date of earliest transaction: acquisition of options and disposal of derivative securities. |
| 03/17/2029 | Date the acquired options become exercisable. |
| 03/17/2035 | Expiration date of the acquired options. |
| 03/18/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.